The global single-photon emission computed tomography market size was valued at 2.55 billion in 2021 and is poised to grow at a significant CAGR of 6.8% during the forecast period 2022-28.  The imaging test single photon emission computed tomography (SPECT) displays how blood flows to tissues and organs. It's utilised to detect cancer, cardiovascular disease, and neurological issues, as well as diagnosis seizures, strokes, stress fractures, infections, and malignancies in the spine. It's a diagnostic nuclear imaging scan that combines computed tomography (CT) and a radioactive tracer. The tracer is radiolabelled, emitting gamma rays that the CT scanner can detect, allowing clinicians to observe how blood flows to tissues and organs.

View Detailed Report Description at      

The single-photon emission computed tomography market segmentation:
By Product Type: Standalone, Bi-Modal, Tri-Modal, Others.
By Applications: Medical Industry, Mechanical Industry, Others.
By Distribution Channel: Hospitals, Diagnostic imaging centers, Ambulatory surgical centers.

The market for single-photon emission computed tomography (SPECT) systems is being driven by the high risks of heart disease, neurological diseases, and cancer, as well as increased patient awareness, increased research and development initiatives, and increased demand for diagnostic imaging devices also including MRI and X-ray devices. Cardiovascular disorders are one of the main causes of death worldwide, according to the WHO. In 2016, cardiovascular disorders were responsible for 37 percent of the 16 million fatalities caused by noncommunicable diseases among those under the age of 70. The development of technologies like SPECT systems that combine X-ray and computed tomography (CT) can help to speed up the whole diagnostic process for diseases like cancer and neurological disorders. The market for single-photon emission computed tomography (SPECT) systems is projected to be hampered by high reagent costs, radiopharmaceutical side effects, and susceptibility to storage conditions.

Request sample report at                                           

Owing to the rising number of cardiac patients, cancer cases, and an ageing population, North America dominates the global market. The medical devices market is driven by early-stage disease diagnosis and treatment, which is predicted to advance the single-photon emission computed tomography (SPECT) systems market in North America. Europe is the world's second-largest market for single-photon emission computed tomography (SPECT) systems, with favourable government policies on health-care infrastructure, favourable regulations on radiopharmaceutical products, the presence of key players, and cancer and cardiovascular disease awareness programmes.

The single-photon emission computed tomography market key players are Philips (The Netherlands) Siemens (Germany) Positron Corporation (U.S) Gamma Medica Inc. (U.S) GE Healthcare (U.K) Hologic Inc. (U.S) Bruker Corporation (U.S) Mediso Ltd., (Hungary) Digirad Corporation CardiArc Ltd. (U.S) Agfa-Gevaert N.V. (Belgium)

About Precision Business Insights:
We are a market research company that strives to provide the highest quality market research insights. Our diverse market research experts are enthusiastic about market research and therefore produce high-quality research reports. We have over 500 clients with whom we have a good business partnership and capacity to provide in-depth research analysis for more than 30 countries. In addition to deliver more than 150 custom solutions, we already have accounts with the top five medical device manufacturers.

Precision Business Insights offers a variety of cost-effective and customized research services to meet research requirements. We are a leading research service provider because of our extensive database built by our experts and the services we provide.

Mr. Satya
Precision Business Insights | Toll-Free: +1 866 598 1553
Email: [email protected]
Kemp House, 152 – 160 City Road, London EC1V 2NX
Web: | D U N S® Number: 852781747